Boosters

Immunocompromised Patients Exhibit Low Antibody Response Even After 2 Doses of mRNA Vaccine

This past March, results of a study monitoring the immune response to the COVID-19 vaccine in solid organ transplant patients indicated that antibodies were detected in only 17% of patients after the first dose of an mRNA vaccine. Since then, data from the same study has been published on the antibody response to the second dose of an mRNA vaccine in immunocompromised persons. Among 658 participants who received two doses of an mRNA vaccine, 15% had measurable antibody response after dose 1 and dose 2. Among 473 participants on antimetabolites, 8% exhibited an antibody response after dose 1 and dose 2. 

Read More »

The NIH Begins Trial on Mixing COVID Vaccine Boosters

A trial funded by the NIH has entered Phase 1/2 testing to study COVID-19 vaccine boosters from different manufacturers on fully vaccinated adults. While it has not been determined whether boosters will be necessary, Dr. Fauci has stated that “we need to prepare for the possibility… to counter waning immunity and to keep pace with an evolving virus”

Read More »

Research on Lasting Immunity to SARS-CoV-2

New research published in Nature has shown that immunity to SARS-CoV-2 can last from one year to possibly a lifetime, as a “SARS-CoV-2 infection induces a robust antigen-specific, long-lived humoral immune response in humans.”

Read More »